4-氨基-3-氯-2,6-二氟吡啶 | 405230-78-6

• 物质功能分类: 医药中间体 - 杂环化合物 - 吡啶类化合物
• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡啶及其衍生物
• 中文名称: 4-氨基-3-氯-2,6-二氟吡啶
• 中文别名: 3-氯-2,6-二氟-4-吡啶胺
• 英文名称: 4-amino-3-chloro-2,6-difluoropyridine
• 英文别名: 3-Chloro-2,6-difluoropyridin-4-amine
• CAS: 405230-78-6
• 化学式: C₅H₃ClF₂N₂
• mdl: MFCD18800801
• 分子量: 164.542
• InChiKey: PQARVFBBRZLDTQ-UHFFFAOYSA-N

物化性质

• 熔点：
  80-84℃

计算性质

• 辛醇/水分配系数(LogP)：
  1.7
• 重原子数：
  10
• 可旋转键数：
  0
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.0
• 拓扑面积：
  38.9
• 氢给体数：
  1
• 氢受体数：
  4

安全信息

• 危险等级：
  9

反应信息

• 作为反应物：
  描述：

  4-氨基-3-氯-2,6-二氟吡啶 在 硫酸 、 potassium nitrate 作用下， 以76.4%的产率得到3-chloro-2,6-difluoro-4-nitraminopyridine
  参考文献：
  名称：

  SYNTHESIS OF HALOGEN-SUBSTITUTED 3-DEAZAADENOSINE AND 3-DEAZAGUANOSINE ANALOGUES AS POTENTIAL ANTITUMOR/ANTIVIRAL AGENTS

  摘要：

  Various 2-halogen-substituted analogues (38, 39, 43 and 44), 3-halogen-substituted analogues (51 and 52), and 2',3'-dihalogen-substituted analogues (57-60) of 3-deazaadenosine and 3-halogen-substituted analogues (61 and 62) of 3-deazaguanosine have been synthesized as potential anticancer and/or antiviral agents. Among these compounds, 3-deaza-3-bromoguanosine (62) showed significant cytotoxicity against L1210, P388, CCRF-CEM and B16F10 cell lines in vitro, producing IC50 values of 3, 7, 9 and 7 muM, respectively. Several 3-deazaadenosine analogues (38, 51, 57 and 59) showed moderate to weak activity against hepatitis B virus.

  DOI：

  10.1081/ncn-100108327
• 作为产物：
  描述：

  五氯吡啶 在 potassium fluoride 、 ammonium hydroxide 、 palladium 10% on activated carbon 、 氢气 作用下， 以 环丁砜 、 乙醇 、 水 为溶剂， 150.0 ℃ 、500.01 kPa 条件下， 反应 6.5h， 生成 4-氨基-3-氯-2,6-二氟吡啶
  参考文献：
  名称：

  一种4-氨基吡啶类化合物的制备方法

  摘要：

  本发明公开了一种4‑氨基吡啶类化合物的制备方法，包括：将4‑氨基‑3‑氯吡啶类化合物或4‑氨基‑3,5‑二氯吡啶类化合物、磷酸钾和催化剂加入到溶剂中，在0～10MPa、0～100℃下反应4～12h。本发明的4‑氨基吡啶类化合物制备方法，所涉及的原料易得或容易自制，成本低廉，本发明的制备方法简单，反应效率高，原料成本低，副产物具有经济价值；同时，本发明所涉及的反应对官能团具有很好的普适性和容忍性。

  公开号：

  CN112321497A

文献信息

• [EN] SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B<br/>[FR] DÉRIVÉS DE SULFAMOYLPYRROLAMIDE ET LEUR UTILISATION EN TANT QUE MÉDICAMENTS POUR LE TRAITEMENT DE L'HÉPATITE B
  申请人：JANSSEN SCIENCES IRELAND UC

  公开号：WO2015118057A1

  公开（公告）日：2015-08-13

  Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  HBV复制的Formula（A）的抑制剂包括立体化学异构体形式，以及它们的盐、水合物、溶剂合物，其中Ra到Rd和R5到R6具有本文所定义的含义。本发明还涉及制备所述化合物的方法、含有它们的药物组合物以及它们在HBV治疗中的单独使用或与其他HBV抑制剂联合使用。
• Novel nucleosides and related processes, pharmaceutical compositions and methods
  申请人：——

  公开号：US20040116362A1

  公开（公告）日：2004-06-17

  The invention provides novel nucleosides and related processes, pharmaceutical compositions, and methods. The novel nucleosides are useful in a wide variety of antiviral, antineoplastic, and antibacterial applications. Preferred embodiments of the instant invention include novel 2 halogen-substituted, 3 halogen-substituted, and 2′,3′dihalogen-substituted analogues of 3-deazaadenosine, and novel 3 halogen-substituted analogues of 3-deazaguanosine. Compounds of the instant invention, including 4-Amino-6-fluoro-1-(&bgr;-D-ribofuranosyl)imidazo[4,5-c]pyridine and 6-Amino-7-bromo-1,5-dihydro-1-&bgr;- D -ribofuranosylimidazo[4,5-c]pyridin-4-one, have exhibited potent antiviral and anticancer activity in vitro. The compounds are also useful in the concomitant treatment of bacterial infections associated with viral infections such as AIDS.

  该发明提供了新颖的核苷和相关的工艺、药物组合和方法。这些新颖的核苷在抗病毒、抗肿瘤和抗菌应用中非常有用。该发明的首选实施例包括新型的2卤代、3卤代和2′,3′二卤代的3-去氨腺苷类似物，以及新型的3卤代的3-去氨鸟苷类似物。该发明的化合物，包括4-氨基-6-氟-1-(&bgr;-D-核糖呋喃基)咪唑[4,5-c]吡啶和6-氨基-7-溴-1,5-二氢-1-&bgr;-D-核糖基咪唑[4,5-c]吡啶-4-酮，在体外表现出强效的抗病毒和抗癌活性。这些化合物也在同时治疗与艾滋病等病毒感染相关的细菌感染方面非常有用。
• Sulphamoylpyrrolamide derivatives and the use thereof as medicaments for the treatment of hepatitis B
  申请人：Janssen Sciences Ireland UC

  公开号：US11078193B2

  公开（公告）日：2021-08-03

  Inhibitors of HBV replication of Formula (A) including stereochemically isomeric forms, and salts, hydrates, solvates thereof, wherein Ra to Rd, and R5 to R6 have the meaning as defined herein. The present invention also relates to processes for preparing said compounds, pharmaceutical compositions containing them and their use, alone or in combination with other HBV inhibitors, in HBV therapy.

  式（A）的 HBV 复制抑制剂 包括立体化学异构体形式，及其盐类、水合物、溶液，其中 Ra 至 Rd 和 R5 至 R6 具有本文所定义的含义。 本发明还涉及制备所述化合物的工艺、含有这些化合物的药物组合物以及它们在 HBV 治疗中单独或与其他 HBV 抑制剂联合使用的情况。
• Selective hydrodechlorination of fluorinated arylamines
  作者：Galina A. Selivanova、Larisa Yu. Gurskaya、Leonid M. Pokrovskii、Vitaliy F. Kollegov、Vitaliy D. Shteingarts

  DOI：10.1016/j.jfluchem.2004.06.006

  日期：2004.12

  Chlorine-containing polyfluorinated anilines and meta-phenylenediamines undergo selective hydrodechlorination easily upon reduction by zinc in aqueous ammonia. A new approach is thus provided to synthetically valuable, partially fluorinated arylamines based on utilizing polyfluorochloroarenes, which are available as intermediates of perfluoroarene production from perchloroarenes. When chlorine atoms are present in positions both ortho and para to the amino group, para chlorine is initially eliminated. Based on this reaction. a one-pot synthesis of partially fluorinated 4-aminopyridines from 3,5-dichlorotrifluoro- and 3-chlorotetrafluoropyridine has been realized. (C) 2004 Elsevier B.V. All rights reserved.
• SULPHAMOYLPYRROLAMIDE DERIVATIVES AND THE USE THEREOF AS MEDICAMENTS FOR THE TREATMENT OF HEPATITIS B
  申请人：Janssen Sciences Ireland UC

  公开号：EP3102572A1

  公开（公告）日：2016-12-14